前房注射Bevacizumab治疗虹膜红变的疗效观察(英文)

Intracameral bevacizumab for treatment of iris rubeosis

目的：观察眼前房注射Bevacizumab（avastin）对虹膜红变的疗效及安全性。方法：5例（5眼）虹膜红变者分别继发于糖尿病视网膜病变,静脉周围炎,静脉阻塞。其中2例为玻璃体切割术后硅油填充眼,给予前房注射0.03ml（0.75mg）Bevacizumb（avastin）。其中1例联合小梁切除手术,1例联合睫状体冷凝术。结果：所有手术眼虹膜新生血管迅速消退,眼内压在联合使用抗青光眼手术或药物后降低,随访2~5mo没有虹膜红变复发,眼内压控制良好。结论：前房注射Bevacizumab（avastin）有效地减轻了虹膜红变,特别是在一些不适合玻璃体腔注射的病例,短期的研究随访证实前房注射迅速消退虹膜新生血管且无明显副作用。

AIM：. To report the curative effect and salty of intracameral bevacizumab （avastin） in patients with rubeosis iridis. METHODS： 5 cases （5 eyes） with iris rubeosis secondary to diabetic retinopathy, retinal periphlebitis （Eales disease） and branch/central retinal vein occlusion, among which 2 cases were silicon oil eyes and were performed intracameral bevacizumab （avastin） 0.03 cc （0.75mg） , one case is combined with trabeculectomy, and another with cyclocryosurgery. RESULTS： The rubeosis of all cases disappeared quickly, meanwhile the intraocular pressure decreased to normal range with the help of anti-glaucoma operation and medicine. There are not any sign of rubeosis again in the 2-5 months follow-up visits and intraocular pressure were well-controlled. CONCLUSION： Intracameral bevacizumab （ avastin ） was an effective treatment for rubeosis, esp, for some cases that can not be injected to vitreous cavity. Short term study of intracameral bevacizumab demonstrated rapid re.gression of rubeosis and well-tolerated injection with no obvious side effects.